ProKidney Corp. reported Tuesday a larger first-quarter loss at $16.7 million as the Winston-Salem biopharmaceutical manufacturer enters a pivotal clinical trial performance period.

MPox is endemic in DRC, and has continued to cause large numbers of cases in the WHO African Region. In April, 2025, the WHO has restated that MPox continues to be a Public Health Emergency of ...

The FDA did not respond to a request for comment. U.S. Health Secretary Robert F. Kennedy Jr. has said that the agency's ...

Some U.S. biotech companies are considering moving early-stage trials of new medicines outside the United States as worry ...

European governments are examining whether U.S. President Donald Trump can force them to pay more for prescription medicines, ...

The United States is advising travellers aged 60 and up to hold off on getting the chikungunya vaccine while it looks into ...

Aurobindo Pharma's CuraTeQ Biologics receives marketing authorization for Zefylti filgrastim biosimilar in the UK and EU.